PLASMAFLO OP OP-08W N/A

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a foreign,health professional report with the FDA on 2019-05-27 for PLASMAFLO OP OP-08W N/A manufactured by Asahi Kasei Medical Co., Ltd..

Event Text Entries

[146224894] This incident occurred in (b)(6) and is reported to fda according to the requirement. Plasmaflo op-08w is similar product of plasmaflo op-05w(a) marketed in us, and is used as plasma separator. We reviewed manufacturing records, quality records of lot# mh5p61. As a result, no abnormality was found in records. No similar event using this lot# mh5p61 was reported globally. Physician considered that this event was serious adverse event of "hemolysis", and the causal relationship between this event and plasmaflo op could not be denied. We could not obtain detail information of this event, according to physician's comment, we considered that this event was serious, and that the causal relationship between plasmaflo op and this event could not be denied because the adverse event occurred during the treatment with op-08w. Hemolysis is described in the package insert of plasmaflo op (i. Preface, e. Precautions): 12. Hemolysis is an adverse reaction that can occur if the tmp increases above 100mmhg (13. 3kpa). 13. Monitor the patient constantly during treatment with the plasmaflo op-05w(a). In the event of any of the following during treatment, immediately ensure the safety of the patient and take appropriate measures in accordance with the directions of the responsible physician. Presence of hemoglobin in separated plasma, due to hemolysis. We will carefully continue to monitor and to be vigilant for the trend of occurrence of this kind of adverse events.
Patient Sequence No: 1, Text Type: N, H10


[146224895] This case occurred in (b)(6). A patient's underlying disease was uraemia. The double filtration plasmapheresis (dfpp) treatment was required to be performed in order to reduce the patient's antibodies before his kidney-transplant surgery. Just after the start of the treatment of dfpp using plasmaflo op-08w used as plasma separator, which is similar product of plasmaflo op-05w(a) marketed in us, the bright red liquid was observed in the separated plasma. The medical staffs judged that the possibility of the patient's hemolysis reaction was suspected, his treatment was stopped.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number8010002-2019-00080
MDR Report Key8643805
Report SourceFOREIGN,HEALTH PROFESSIONAL
Date Received2019-05-27
Date of Report2019-04-29
Date of Event2019-03-27
Date Mfgr Received2019-04-29
Device Manufacturer Date2018-06-01
Date Added to Maude2019-05-27
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactMR. AKITAKE YAMASHITA
Manufacturer Street1-1-2 YURAKUCHO, CHIYODA-KU
Manufacturer CityTOKYO 100-0006
Manufacturer CountryJA
Manufacturer Postal100-0006
Manufacturer G1ASAHI KASEI MEDICAL MT CORP.
Manufacturer StreetOITA WORKS 2111-2 OAZA SATO
Manufacturer CityOITA-SHI, OITA 870-0396
Manufacturer CountryJA
Manufacturer Postal Code870-0396
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NamePLASMAFLO OP
Generic NamePLASMA SEPARATOR
Product CodeMDP
Date Received2019-05-27
Model NumberOP-08W
Catalog NumberN/A
Lot NumberMH5P61
OperatorHEALTH PROFESSIONAL
Device AvailabilityN
Device Eval'ed by MfgrR
Device Sequence No1
Device Event Key0
ManufacturerASAHI KASEI MEDICAL CO., LTD.
Manufacturer Address1-1-2 YURAKUCHO CHIYODA-KU TOKYO 100-0006 JA 100-0006


Patients

Patient NumberTreatmentOutcomeDate
101. Other 2019-05-27

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.